Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

DocASAP Honored as a 2020 “Technology Fast 500” Winner by Deloitte


News Image

“We’re honored to be recognized by Deloitte as one of the fastest growing technology companies in North America,” said Puneet Maheshwari, co-founder and CEO of DocASAP.

DocASAP, the industry’s most advanced patient access and engagement platform for health systems, health plans and physician groups, today announced its inclusion on Deloitte’s Technology Fast 500™ list, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 26th year. DocASAP grew 215% during the reporting period.

“We’re honored to be recognized by Deloitte as one of the fastest growing technology companies in North America,” said Puneet Maheshwari, co-founder and CEO of DocASAP. “The world has changed drastically over the last year and this accolade is a testament to our team’s resilience and dedication to ensuring optimal health through safe and timely care.”

DocASAP is mission-focused on reducing barriers to care. It’s patient access and engagement platform enables advanced patient matching and navigation to the right care setting–whether virtual or in-person–based on the provider’s specific care delivery protocols. Patient engagement tools, such as actionable reminders and care-driven outreach, help providers improve patient outcomes and loyalty while reducing costs.

“For more than 25 years, we’ve been honoring companies that define the cutting edge and this year’s Technology Fast 500 list is proof positive that technology — from software and digital media platforms, to biotech — truly does permeate so many facets of our lives,” said Paul Silverglate, vice chairman, Deloitte LLP and U.S. technology sector leader. “We congratulate this year’s winners, especially during a time when innovation is needed more than ever to address the monumental challenges posed by the pandemic.”

“Each year the Technology Fast 500 listing validates how important technology innovation is to our daily lives. It was interesting to see this year that while software companies continued to dominate, biotech companies rose to the top of the winners list for the first time, demonstrating that new categories of innovation are accelerating in the pursuit of making life easier, safer and more productive,” said Mohana Dissanayake, partner, Deloitte & Touche LLP, and industry leader for technology, media and telecommunications, within Deloitte’s audit and assurance practice. “We extend sincere congratulations to these well-deserved winners — who all embody a spirit of curiosity, and a never-ending commitment to making technology advancements possible.”

For a complete list of Deloitte’s 2020 Technology Fast 500 winners visit, http://www.fast500.com.

About Deloitte’s 2020 Technology Fast 500™

Now in its 26th year, Deloitte’s Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2016 to 2019.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About DocASAP

DocASAP provides the industry’s most advanced patient access and engagement platform for health systems, health plans and physician groups. DocASAP empowers organizations to navigate patients to the optimal provider and care setting at the right time throughout their access journey, helping improve outcomes, reduce costs and create a better patient experience. Backed and promoted in the market by Aetna, Optum and UnitedHealthcare, DocASAP builds unique payer-provider connections with an eye toward simplified access, increased care compliance and improved population risk management. For more information, visit http://docasap.com or follow on Twitter @DocASAP.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see http://www.deloitte.com/about to learn more about our global network of member firms.

Share article on social media or email:

Phoenix Technology Group congratulates its ophthalmic photographers for selection to leadership roles in the OPS


We are so thrilled …and gratified that OPS has recognized not only their expertise but also their tireless dedication helping fight blindness.

Today, Phoenix Technology Group (Phoenix), a leading provider of advanced ophthalmic imaging solutions for researchers and clinicians, is pleased to congratulate Elizabeth (Libba) Affel, global ophthalmic imaging trainer, as the new President for the Ophthalmic Photographers’ Society (OPS) for a two-year term. We are also pleased to congratulate Denise Armiger, global ophthalmic clinical trainer for her new post on the Board of Education at OPS, as well as her appointment to a board position with the Foundation Fighting Blindness. The OPS is the premier educational and training resource for ophthalmic imaging in the medical profession and includes photographers, physicians, optometrists, ophthalmic technical personnel, and scientists.

Affel has nearly 40 years of ophthalmic imaging and visual diagnostic experience. After her first job in animal research at Hahnemann Hospital, she joined the clinical lab at Wills Eye Hospital, followed by a role imaging in the ultrasound and electrophysiology department where she was the first woman hired. In 1990, Affel was promoted to lead the department and in 2008, she became the first ever Director of the Diagnostic Testing Center. Affel has also spent the last ten years certifying physicians and imagers for clinical trials with Annesley Eye Brain Center. She joined Phoenix in 2017 as Global Clinical trainer, working with clinicians and ophthalmic imagers around the world. Affel joined OPS in 2000 and was elected to the OPS Board of Directors in 2012. Her storied career includes awards from JCAHPO and Wills Eye Hospital. She also serves as a committee member for the Center for Academic and Global Ophthalmology, and Board positions with the Philadelphia Regional Ophthalmic Society and the Ophthalmic Medical Technology Program with Camden County College.

The Ophthalmic Photographers’ Society has been the premier society for ophthalmic photographers for the past 50 years. The organization’s main focus is to educate and certify ophthalmic photographers, ensuring imagers are taking routine, standardized images for ophthalmologists to successfully screen patients for various eye diseases. OPS convenes two meetings per year with various lectures, certification trainings, “crash-courses” for novices and professional development to the ophthalmic imaging community. Upon being elected president Affel notes “I have loved being a part of the OPS Board these past eight years and appreciate how it has helped make me a better imager and a better trainer for Phoenix. It is fulfilling to serve as a mentor and to help pave the way for the next generation of photographers.”

Affel’s fellow global clinical trainer at Phoenix, Denise Armiger, was recently elected to serve on the OPS Board of Education for a four-year term. This arm of OPS, composed of eleven members, functions specifically to set the education standards for the organization, as well as to plan and produce the curricula for the annual program, regional and mid-year programs and coordinate the increasingly crucial online education modules. Armiger’s focus for her term will include creating technical summary documents for CME credits and serving as a mentor for ophthalmic imagers.

Armiger joined Phoenix last year from Leica Microsystems (formerly Bioptigen), where she managed global clinical training and product marketing and trained on the first Intraoperative OCT in the operating room. Prior to that, she was a Senior Applications Specialist with Heidelberg Engineering, where she installed equipment onsite, and trained in clinical and research imaging. Earlier in her career, Armiger held roles as the Director of Diagnostic Imaging at Columbia University and ophthalmic photography with Emory University. Her past work with OPS includes multiple lectures on OCT, Fluorescein Angiography, rare eye diseases and most recently, she built content and training programs for the Phoenix team to present and train virtually during the COVID-19 pandemic. Armiger was also recently named to the Board of Directors for the nonprofit Foundation Fighting Blindness which focuses on research and public health education programs concerning inherited blinding eye diseases.

“We are so thrilled for Libba and Denise and gratified that OPS has recognized not only their expertise but also their tireless dedication helping fight blindness,” says Scott Carr, CEO of Phoenix. “For both Libba and Denise, ophthalmic imaging and training is not merely a vocation. It’s a passion. They show their commitment everyday training imagers and photographers globally to use Phoenix ICON™ imaging systems while continuing to pay it forward by helping to attract more talented imagers into the profession.”

About Ophthalmic Photographers’ Society: (OPS) is the premier educational and training resource for ophthalmic imaging in the medical profession, including photographers, physicians, optometrists, ophthalmic technical personnel, and scientists. The OPS is the only organization providing certification in the fields of fundus photography, fluorescein angiography and OCT imaging and is open to anyone having an interest in any aspect of photography/imaging of the eye and ophthalmology. With members from 27 countries, OPS is the oldest established society in the world dedicated to ophthalmic imaging. Imaging technology continues to evolve at a rapid pace; the OPS sponsors regional, national, international and online educational programs that provide the most comprehensive and diverse training for ophthalmic technical personnel. A hallmark of the society is its emphasis on education, certification and mentoring – imagers learning skills from other imagers. Networking with other imaging professionals facilitates new insights and career development. http://www.opsweb.org

About Phoenix Technology Group: Phoenix Technology Group empowers people to see: we empower researchers to see more in their fight to prevent blindness; we empower clinicians to see more in their fight to save sight. We do that by providing clinicians and researchers around the world with stunning retinal images, coupled with timely and accurate data about the retina and the eye. Founded by Bert Massie, Ph.D., inventor of the first digital camera for pediatric retinal imaging, our company created the Phoenix MICRON™ platform for in-vivo imaging of animals in eye research. Phoenix MICRON is the standard of excellence for researchers worldwide: ten of the top twelve research institutions employ a Phoenix MICRON solution. In 2017, the company launched the Phoenix ICON™ platform which reinvented wide-field retinal imaging for human clinical applications. In 2020, Phoenix launched the Phoenix ICON GO portable imaging system, enabling clinicians and ophthalmic imagers the ability to take the camera system to the patient, while delivering the same stunning high-contrast, high-resolution images as the cart-based system. Recognizing that telemedicine is the future of ROP screening, in 2018, Phoenix acquired FocusROP and relaunched it as Phoenix CONNECT, the most widely adopted telemedicine platform for ROP screening. With this acquisition, retinal images from any wide-field retinal imaging camera can, in seconds, be delivered to physicians remotely, saving them time while providing better documentation.

Share article on social media or email:

Operation Smile Hosts Virtual Regan Resident Leadership Conference with Dr. John G. Meara as Keynote Speaker


News Image

The virtual conference starts Friday, Nov. 20 from 9:00 a.m. to 2:15 p.m. EST and will feature presentations from a variety of industry experts.

Operation Smile is hosting its first Virtual Regan Resident Leadership Conference with the support of the Harbourton Foundation on Friday, Nov. 20, 2020. Dr. John G. Meara is scheduled to deliver the keynote speech. The Kletjian Professor of Global Surgery, Director of the Program in Global Surgery and Social Change and Professor of Surgery in the Department of Surgery at Harvard Medical School, Dr. Meara has a particular interest in augmenting the delivery of quality surgical and anesthesia care in low-resource settings through long-term capacity building. His clinical interests are in the area of craniofacial conditions and cleft lip and cleft palate. Dr. Meara will address the changing global surgery landscape in recent years and in the wake of COVID-19’s impact.

The exclusive virtual event, “The Changing Landscape and Innovation in Global Surgery and Implications for Comprehensive Cleft Care,” will offer opportunities for shared learning, networking and collaboration between Operation Smile Regan fellows, residents, recent graduates and world-renowned experts regarding global surgery, innovations and its implications for comprehensive cleft care.

“To see the next generation of leaders in plastic surgery, anesthesia and pediatrics come together as part of the Operation Smile Regan Resident Leadership Program is inspiring,” says Operation Smile Chief Medical Officer Dr. Ruben Ayala. “These are professionals who believe that medicine, humanitarian assistance and capacity building have the power to bring humanity together. Through the Regan fellowship, mentors and mentees forge a clear path towards the fulfillment of their service and the positive changes in the lives of children and communities we all hope for.”

Supported by the Harbourton Foundation, the Operation Smile Regan Resident Leadership Program plays a pivotal role in increasing the capacity and skills of senior residents specializing in surgery, anesthesiology and pediatrics, empowering them to deliver high-quality care. Through this program, senior residents have the opportunity to volunteer on an Operation Smile medical program and other training opportunities. This provides the residents with the unique opportunity to develop professional skills, collaborate with a diverse care team while bringing high-quality care to people living with cleft lip and cleft palate around the world.

The virtual conference starts Friday, Nov. 20 from 9:00 a.m. to 2:15 p.m. EST and will feature presentations from a variety of industry experts including Operation Smile Co-Founder and CEO, Dr. Bill Magee; Dr. Donald Lalonde, a professor in the division of plastic and reconstructive surgery at Dalhousie University in Saint John, New Brunswick, Canada; Dr. Jeffrey R. Marcus of Duke Children’s Health Center Plastic Surgery Clinic; and Dr. Nicole Ann Shilkofski, assistant professor of pediatrics and anesthesiology and critical care medicine at the John Hopkins University School of Medicine.

About Operation Smile

Operation Smile revolutionized cleft surgery globally in 1982. With nearly four decades of experience as one of the largest surgical volunteer-based nonprofits, Operation Smile staff, its private-public partnerships and thousands of volunteers have improved the health and dignity of patients with cleft conditions, helping them to better breathe, eat, speak and live lives of greater quality and confidence. While one cleft surgery can bring immediate transformation to a child’s life in as little as 45 minutes, Operation Smile is committed to providing patients with health that lasts—being there to offer patients additional surgeries, dentistry, psychological services, speech therapy and other essential cleft treatments. Its training and education programs elevate local surgical standards and entire health systems to aid safe surgery and strengthen a global network to reach more people earlier in their lives. You can learn more about their transformative and healing work by visiting operationsmile.org or by following @operationsmile on social media.

About the Harbourton Foundation

Established in 1985 in Princeton, New Jersey, the Harbourton Foundation is the philanthropic arm of the Regan family, founded by James (Jay) Regan and his wife, Amy. The foundation’s giving focuses on organizations that tackle issues within human rights and the environment, among others. The Harbourton Foundation has been committed to cultivating emerging medical talent since 2006, when the Resident Leadership Program launched. In 2017, the Regan family made a five-year commitment through the Harbourton Foundation to continue the Resident Leadership Program’s growth and progress.

###

Share article on social media or email:

Farlong Pharmaceutical Offers Formulas and Ingredients to Relieve Symptoms of Influenza, Cold, Cough and Respiratory Illnesses this Winter


Farlong’s Lung Booster 1 is derived from Ling Dan Cao Granules and is used to protect the throat, lung and respiratory tract system.

Farlong Pharmaceutical, a vertically integrated, plant-based ingredient and supplement company, is offering formulas and ingredients to relieve seasonal influenza-related symptoms including a sore throat, cough and fever amongst others. These products include Lung Booster 1 (Ling Dan Cao Granules), Revitalize Immunity Boost (Nan Ban Lan Gen Granules), Rescue Respiratory Relief (Ping Chuan Granules) and Renew Lung Support (Qing Wen Xuan Fei Granules). These formulas have been used in clinics across the U.S. such as Acupuncture Corporation of America (ACA)’s franchised clinics, and are widely favored by both practitioners and patients.

“This winter, both consumers and practitioners are looking for natural ways to boost their immune systems and remain healthy,” Jing Struve, CEO and executive director of Farlong Pharmaceutical. “Traditional Chinese medicine (TCM) has been in practice for thousands of years, and we are proud to provide top quality ingredients that are recognized for their effectiveness to help relieve the symptoms of numerous ailments.”

Due to the Coronavirus pandemic and increased demand, Farlong introduced Lung Booster 1, a dietary supplement, earlier this year. Lung Booster 1 is derived from Ling Dan Cao Granules and is used to protect the throat, lung and respiratory tract system, which in turn can help to relieve influenza symptoms. It helps to relieve a sore throat within hours when mixed in warm water and sipped slowly. The granules are developed from the whole plant extract from Chou Ling Dan Cao that is geologically unique to Yunnan Province, a region known for harvesting herbs used in TCM. For more than 500 years, Chou Ling Dan Cao has been used to cool the body’s internal temperature, detoxify and soothe the throat, clear lung-heat and resolve phlegm. Lingdancao was recently named by Guangzhou Medical University, Yunnan University of Traditional Chinese Medicine, and Yunnan Health Department Health Supervision Bureau as one of the recommended natural herbs for relieving symptoms of COVID-19.

Revitalize Immunity Boost, Rescue Respiratory Relief and Renew Lung Support are available through Farlong’s professional line for TCM practitioners, acupuncturists or dietary supplement brand owners to white label. Especially during influenza season, individuals can strengthen their immune system with Revitalize Immunity Boost, made from Nan Ban Lan Gen Granules which are used for clearing internal heat, cooling blood, supporting the health of the throat and lung, and rebuilding the body’s natural balance. The formula is made of Baphicacanthus cusia extract (Ban Lan Gen) and Isatis indigotica extract (Da Qing Ye). Rescue Respiratory Relief contains Ping Chuan Granules which help to relieve asthma related coughs, throat and lung infections, dissolve phlegm, and strengthen the immune system. The formula is made of Rhododendron dauricum extract (Man Shan Hong), Platycodon grandiflorum extract (Jie Gen), and Glyeyrrhiza uralensis extract (Zhi Gan Cao). Renew Lung Support is formulated using Qing Wen Xuan Fei Granules, which are popular among practitioners due to its immediate effectiveness to suppress influenza symptoms, such as sore throat, phlegm, and fever related body aches.

For more than 20 years, Farlong has created natural and herbal supplements to promote a healthy and natural life, focusing on top quality ingredients and ancient Chinese roots. Farlong produces Ginseng Plus® Panax Notoginseng, Lifeflower® breviscapine and AstaBest® Astaxanthin from seed to shelf, beginning at their GAP certified farms located in Yunnan Province, China. The geographical area of the farm’s location is known for harvesting specific medicinal Chinese herbs, proven to benefit the health and improvement for a variety of health conditions. Farlong combines traditional processing methods with the most advanced techniques, ensuring that all decoction ingredients are transferred to full-spectrum concentrated ingredients while achieving greater levels of quality, stability and effectiveness.

About Farlong Pharmaceutical:

Since 1998, Farlong Pharmaceutical combined ancient Oriental medicine and modern technology to create a line of natural and safe products that promote a healthy life. Farlong is a vertically integrated herbal ingredient and supplement company with its own GAP (Good Agricultural Practice) certified cultivation base, cGMP (Current Good Manufacturing Practice), certified manufacturing facilities and distribution channels for its unique and effective ingredients and formulas, including InnerPure® for colon detoxing, Lifeflower® breviscapine for cognitive health, Ginseng Plus® Panax Notoginseng™ for heart health and AstaBest® Astaxanthin for antioxidant nutrition. For more information, visit Farlong.com for supplements and 300+ ingredients, and follow on Facebook, Twitter and Instagram.

Share article on social media or email:



American Parkinson Disease Association Releases Symptom Tracker Mobile App With Expanded Features


APDA Symptom Tracker App Logo

“As a movement disorder specialist, the more my patients can tell me about their symptoms, the more I can help them.The upgraded APDA Symptom Tracker App benefits not only the patient, but it helps me as their doctor.” – Dr. Rebecca Gilbert

The American Parkinson Disease Association (APDA) launches today a new and improved APDA Symptom Tracker App 2.0 – a highly-specialized mobile application for people living with Parkinson’s disease (PD). The updated version remains free of charge and features enhanced functionality which will significantly improve the ability of a person with Parkinson’s disease (PD) to easily and accurately track their PD symptoms and medications, and relay that important information to members of their medical team; with the ultimate goal of receiving better, more personalized care. A Spanish-language version of the app is now available as well, which enables a much larger audience to take advantage of this technology and builds upon APDA’s commitment to better serve and support under-represented PD communities.

With a mission to help everyone impacted by PD live life to the fullest, APDA originally developed the APDA Symptom Tracker App in 2019 as an important tool to help people play a more active role in their PD care. After a year of user feedback and continued research, the APDA app has now been significantly upgraded with features that make it even more useful as part of an integrated PD care plan. The development of this app and its upgrades were made possible by generous financial support from Acadia Pharmaceuticals Inc.

The APDA Symptom Tracker App 2.0 guides people through a simple set of questions that has them rate how certain motor symptoms (such as tremor, rigidity, balance) and non-motor symptoms (hallucinations, delusions, fatigue, anxiety, depression, and others) are affecting them. It then creates a graph indicating which symptoms are most impacting their quality of life in which can be saved in the “My Library” section of the app, and can also be emailed directly to members of their health care team, right from the app. Over time, people can compare the results to see if certain symptoms are getting worse, and determine which symptoms need to be addressed more urgently than others.

The improved APDA Symptom Tracker App 2.0 boasts the following new features:


  • An interactive medication tracker where you can enter the specific medications/doses and the time of day you take them which helps identify opportunities for better symptom management (medication dosage/timing is an incredibly specific and often tricky aspect of life with PD)
  • Helpful notifications and reminders including:


             reminders to enter symptom data into the app

             push notifications about helpful education programs and updates on treatments

             reminders to share information with the clinician prior to appointments

  • A Spanish-language version that has been fully created for and by Spanish-speaking people (not simply translated from the English version)

These newly-added features are important because everyone experiences PD differently, and symptoms can vary greatly day by day. The more specific someone can be with their health care team about the types of symptoms they’re experiencing, and the timing of their medication, the better the doctor(s) can tailor a treatment plan specifically for each person. But it can be hard for people to remember how certain symptoms have or have not affected them since the last time they connected with their health care team, or if they missed a medication dose.

“As a movement disorder specialist, the more my patients can tell me about their symptoms, the more I can help them. I can see how they’re feeling at that one moment, but to be able to see on a chart how they’ve been feeling at other times since I last saw them would be hugely beneficial for me” states Rebecca Gilbert, MD, PhD, Chief Scientific Officer, APDA. “And now if they track their medications with the app as well, it will help me see possible correlations between dosing and their symptoms. The upgraded APDA Symptom Tracker App benefits not only the patient, but it helps me as their doctor.”

The APDA Symptom Tracker also has a special “Questions for the Doctor” feature that generates a list of suggested follow-up items for people to review with their doctor about symptoms and concerns they are currently experiencing, but also about preventative care. This will help them be more proactive in managing their PD. They can bring a printout of the questions to their appointment, so they don’t forget to ask any that are important to them. The app also features a useful list of resources that connects them directly to a wealth of quality, credible PD information.

“Acadia is pleased to support the development of the APDA Symptom Tracker as a helpful tool for patients, caregivers and providers to keep track of motor and non-motor symptoms associated with Parkinson’s,” said Ponni Subbiah, M.D., M.P.H., Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer at Acadia. “With the features of this latest release, which includes a Spanish-language version of the app, we hope to broaden the reach of this important resource for the PD community.”

The APDA Symptom Tracker App can help people have more meaningful conversations with their healthcare team and better manage their disease. The app can be downloaded for free from the Apple App Store or Google Play.

About the American Parkinson Disease Association:

The American Parkinson Disease Association (APDA) is the largest grassroots network dedicated to fighting Parkinson’s disease (PD) and works tirelessly to help the more than 1 million Americans with PD live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $207 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease. To join us in the fight against Parkinson’s disease and to learn more about the support APDA provides nationally through our network of Chapters and Information & Referral (I&R) Centers, as well as our national Research Program and Centers for Advanced Research, please visit us at http://www.apdaparkinson.org.

Media Contact: Eloise Caggiano, ecaggiano@apdaparkinson.org, 718-981-2950

Share article on social media or email:

PRMA Plastic Surgery Welcomes Newest Breast Reconstruction Surgeon to the Team


PRMA Welcomes Dr. Andrew Gassman to the surgical team!

PRMA Welcomes Dr. Andrew Gassman to the surgical team!

I am honored to join a practice dedicated to serving patients with a mission of rebuilding lives after breast cancer.

PRMA Plastic Surgery | Center for Advanced Breast Reconstruction opened its doors to serve the local San Antonio, Texas breast cancer community over 25 years ago. Since the practice welcomed its first patient in 1994, PRMA has grown to be one of the leading breast reconstruction centers in the world.

To expand patient care, PRMA is excited to welcome Dr. Andrew Gassman to the team!

Dr. Gassman is a board-certified plastic surgeon and breast reconstruction surgeon with extensive experience in autologous reconstruction options like the DIEP flap.

To date, PRMA has performed over 10,000 state of the art breast reconstruction procedures on patients following a mastectomy or lumpectomy. The practice continues to welcome patients from across Texas and around the world!

Dr. Gassman says he is “honored to join a practice dedicated to serving patients with a mission of rebuilding lives after breast cancer.”

Dr. Gassman earned his medical degree from Loyola University Stritch School of Medicine in Maywood, Illinois. He completed his plastic and reconstructive surgery residency at UCLA David Geffen School of Medicine in Los Angeles, California and a general surgery residency, as Chief of Surgical Resident Education, at Loyola University Medical Center in Maywood Illinois. Following his residency, Dr. Gassman completed his fellowship in breast and reconstructive microsurgery, with a subspecialty in facial reanimation at UTSW Department of Plastic and Reconstructive Surgery in Dallas, Texas.

An active researcher with a number of publications, book chapters and abstracts, Dr. Gassman’s clinical research interests include pain reduction after breast reconstruction, enhanced patient recovery after reconstruction, and multi free flap breast reconstruction and perforator free flap reconstruction. Dr. Gassman’s also has a passion for teaching and has spent many years as an associate professor teaching future plastic surgeons advanced breast reconstruction techniques.

His specialized training led him to PRMA where he joins plastic surgeons Peter Ledoux, Steven Pisano, Chet Nastala, Minas Chrysopoulo, Gary Arishita, Oscar Ochoa, and Ramon Garza III performing the latest microsurgical breast reconstruction techniques and lymphedema surgery.

Dr. Gassman is available for appointments starting in January of 2021 at PRMA’s Medical Center office located at 9635 Huebner Road, San Antonio, TX 78240. To schedule call 800-692-5565

Share article on social media or email:

a Gold and a Silver for Two GSK Programs


News Image

“The Viscira team worked with us to bring our online pharmacist module to market. We created exciting and engaging animated superhero characters that came to life with real video to help pharmacists improve adult immunization rates…” said Chris Lowry, Marketing Manager, SHINGRIX, at GSK.

Viscira, a leading provider of innovative digital marketing solutions and software applications for the life sciences industry, announced today that the Academy of Interactive and Visual Arts has selected Viscira as a Gold Davey Award winner for its interactive eLearning module for adult vaccines. Additionally, Viscira secured a Silver Davey Award for an augmented reality (AR) program for lupus patients and caregivers. Both programs were done in close collaboration with GlaxoSmithKline (GSK).

The interactive eLearning module is a dynamic, engaging module that provides pharmacists with information about adult vaccinations. The module includes built-in scenarios and quiz questions that can be used by all pharmacists to help with training needs. Located publicly at http://www.gsk-vacciNATION.com, pharmacists are able to access the module at their convenience from any device.

“The Viscira team worked with us to bring our online pharmacist module to market. We created exciting and engaging animated superhero characters that came to life with real video to help pharmacists improve adult immunization rates by enabling them to have better conversations with their patients,” said Chris Lowry, Marketing Manager, SHINGRIX, at GSK.

The augmented reality program used a small physical house in conjunction with an iPad loaded with a mobile app that came to life with both AR and video components. The physical house has four separate rooms, and each room represents a different type of individual dealing with lupus —the overwhelmed patient, the actor patient, the warrior patient, and the caregiver. The AR and video components of the app experience allow patients to see and identify with someone who has the same thoughts, feelings, and daily struggles with lupus.

The Davey Awards is in its 16th year and is overseen and sanctioned by the Academy of Interactive and Visual Arts (AIVA), an invitation-only body consisting of top-tier professionals from a “Who’s Who” of acclaimed media, communications, advertising, creative, and marketing firms. AIVA members include executives from organizations such as Conde Nast, Disney, GE, Keller Crescent, Microsoft, Monster.com, MTV, Push, Publicis, Sesame Workshops, The Marketing Store, Worktank, Yahoo!, and many others.

About Viscira

Viscira is dedicated to the design and development of innovative digital marketing solutions and applications for the life sciences industry. Viscira provides a suite of programs that integrate best-in-class technology to deliver engaging and memorable user experiences and content via various electronic channels. Viscira is part of WPP, the largest agency holding company in the world. For more information, please visit the company’s website at http://www.viscira.com or contact Noёl Ashekian at (617) 429-0834.

Share article on social media or email:

Asymmetrex Publishes the First Report of Immortal DNA Strands in Human Stem Cells


Example of a tissue stem cell (left) holding on to its immortal DNA strands after dividing to produce a maturing tissue cell (right).

…immortal DNA strands must exist to explain how immortal stem cells avoid higher cancer rates.

What does it mean for multiplying cells in the body to be immortal? The cell DNA is being replicated over and over again while being divided equally between new cells produced by cell divisions. All the new cell components produced by the DNA code are mixing with the old cell components and being divided between the new cells. So, every cell is a new cell. There is nothing really immortal about any of them. Right?

Not quite. Stem cells responsible for renewing other mature body cells are different. For a long time, tissue cell scientists had a somewhat nebulous idea that stem cells had a special longevity in organs and tissues – that they were immortal cells, lasting for as long as the human lifespan. However, no one had a molecular concept for this idea of stem cell immortality until John Cairns, a pioneer of DNA replication, started thinking about DNA mutations and cancer in the 1970’s.

Cairns predicted that stem cells did something unique with their DNA code. He said they held on to one strand of every one of their many chromosomes and never shared those DNA strands with the tissue cells they renewed. Cairns called these immortal DNA strands. Cairns argued that immortal DNA strands must exist to explain how immortal stem cells avoid higher cancer rates.

Asymmetrex director James Sherley calls the immortal strand hypothesis the Carpenter’s Rule for stem cells. Good carpenters avoid creeping measurement errors by using a ruler or the same piece of wood to measure duplicates. Too many DNA duplication errors in cells make them cancerous. Cairns proposed that stem cells were smart carpenters, keeping and using the same DNA strands for making their many replicate copies over the human lifespan.

Prior to Asymmetrex’s new report, published in a special issue of the peer-reviewed journal Symmetry, there were many publications on the presence of immortal DNA strands in stem cells of other species, including molds, plants, insects, and mice. Low levels of immortal DNA strands were also reported for human cancer cells.

The new report from Asymmetrex describes the presence of immortal DNA strands in human liver stem cells. The SACK-Xs 12(3) stem cells used in the study were developed more than a decade earlier using Asymmetrex’s patented SACK tissue stem cell expansion technology. SACK-Xs 12(3) human liver stem cells are distributed for research by Kerafast. They are the first and only commercial human tissue stem cell product supplied with their stem cell-specific dosage, certified by Asymmetrex.

The new report brings an important closure for an ingenious scientific deduction by a remarkable scientist, John Cairns, recently deceased. Now that normal human tissue stem cells are confirmed to have immortal DNA strands, scientists can get on with the business of leveraging this knowledge to a better understanding of tissue stem cells for improving human health.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Share article on social media or email:

Latest Developments and Keys to Successful Compliance with FDA Regulations and Guidance Webinar Dec. 2, 2020


WCG FDAnews

WCG FDAnews

Advertising and Promotion Compliance:

Latest Developments and Keys to Successful Compliance with FDA Regulations and Guidance

An FDAnews Webinar

Wednesday, Dec. 2, 2020, 11:00 a.m.-12:30 p.m. EST

https://www.fdanews.com/adpromocompliance

Promotional activities can be magnets for warning letters or untitled letters.

How can one successfully comply with the FDA’s complex advertising and promotion guidelines?

Join Covington & Burling LLP’s Stefanie A. Doebler, a Partner, and Christopher Hanson, Special Counsel, for an introduction to advertising and promotion principles, including requirements for promotion (incorporating claims substantiation, fair balance and off-label promotion) and key differences between drug and device promotion.

They will use case studies from recent enforcements to explain the most important risk areas, including:


  • Key statutory definitions used in the Federal Food, Drug and Cosmetic Act (FD&C Act), such as misbranded, labeling and false and misleading
  • The primary requirements for advertising and promotion set forth in the FD&C Act and implementing regulations
  • The FDA’s recent guidance on promotion consistent with the approved labeling described in its 2019 guidance, “Medical Product Communications That Are Consistent With the FDA-Required Labeling”
  • The scope of the prohibition on preapproval promotion, 21 CFR 312.7, 812.7
  • The difference between promotion and disease awareness communications, described in FDA’s draft guidance, “‘Help-Seeking’ and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms”

What one doesn’t know about drug and device advertising and promotion will hurt you. Arm oneself against violations with this webinar.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally to learn about our special multisite discount.

Webinar Details:

Advertising and Promotion Compliance:

Latest Developments and Keys to Successful Compliance with FDA Regulations and Guidance

An FDAnews Webinar

Wednesday, Dec. 2, 2020, 11:00 a.m.-12:30 p.m. EST

https://www.fdanews.com/adpromocompliance

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/adpromocompliance

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

AAAAI-Supported Food Allergy Bill Passes the House of Representatives


AAAAI Logo

“While it still needs to pass the Senate before it can be signed into law, this bill will do several things to improve the health and safety of Americans living with food allergies.” – AAAAI President Mary Beth Fasano, MD, MSPH, FAAAAI

The Food Allergy Safety, Treatment, Education, and Research (FASTER) Act (H.R. 2117), a bill supported by the AAAAI, passed the House of Representatives today with a unanimous voice vote. The FASTER Act directs the Centers for Disease Control and Prevention (CDC) to expand data collection of information related to food allergies and specific allergens, and revises the definition of major allergen to specifically include sesame. House Energy and Commerce Committee Chairman Frank Pallone (D-NJ), Ranking Member Greg Walden (R-OR), and Representative Doris Matsui (D-CA) spoke in support of the bill.

“The AAAAI joins with our Patient Advocacy Organization partners in celebrating the news that H.R. 2117 has successfully passed the House of Representatives,” said AAAAI President Mary Beth Fasano, MD, MSPH, FAAAAI. “While it still needs to pass the Senate before it can be signed into law, this bill will do several things to improve the health and safety of Americans living with food allergies, including revising the definition of major allergens to include sesame, which is tremendously significant.”

H.R. 2117 is sponsored by Representative Doris Matsui, who was joined by more than 90 bipartisan cosponsors. “Food allergies impact the daily lives of so many Americans, including our friends and family members,” said Congresswoman Matsui. “Some of these food allergies can be serious and potentially be life-threatening diseases, and it’s become abundantly clear to me that we need more research and evidence-based solutions to help understand, treat, and maybe one day prevent food allergies. I hope this legislation will provide progress treating allergies and improving the lives of those suffering from them.”

The AAAAI continues to advocate for congressional adoption of H.R. 2117 which would advance recommendations from the National Academy of Medicine report “Finding a Path to Safety in Food Allergy: Assessment of the Global Burden, Causes, Prevention, Management, and Public Policy,” including strengthening data collection on the prevalence of food allergies, and adding sesame to the list of allergens required to be listed on food labels, as well as providing flexibility for the Secretary of Health and Human Services to add any other food ingredients determined by regulation to be a major food allergen. The AAAAI joins its stakeholder partner FARE in support of this important legislation.

Passage of the FASTER Act comes after the Food and Drug Administration (FDA) recently issued a draft guidance titled “Voluntary Disclosure of Sesame as an Allergen”. The document encourages food manufacturers to voluntarily declare sesame in the ingredient list on food labels. Comments on the draft guidance are due January 11, 2021. Additionally, the recently released Senate appropriations bill included a statement about allergen labeling expressing concern that the FDA has failed to take further action to require labeling for sesame and urging the agency to act swiftly to address this risk by requiring the same labeling for sesame as other major food allergens. Also included was report language requested by the AAAAI and other stakeholders which recognizes the prevalence of food allergy in the pediatric and adult communities, commends the ongoing work of the National Institute of Allergy and Infectious Diseases (NIAID) and the Consortium of Food Allergy Research (CoFAR), and encourages the NIAID to expand its clinical research network to add new centers of excellence in food allergy clinical care and to select such centers from those with a proven expertise in food allergy research.

AAAAI’s professional governmental relations team and physician leadership continue to make a priority of encouraging federal research support for food allergies and related advocacy activities.

You can learn more about food allergies on the American Academy of Allergy, Asthma & Immunology website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

###

Share article on social media or email: